This company listing is no longer active
Acerus Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Key information
-22.8%
Earnings growth rate
23.7%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -32.5% |
Return on equity | n/a |
Net Margin | -924.3% |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Acerus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 3 | -28 | 20 | 7 |
30 Jun 22 | 3 | -29 | 20 | 7 |
31 Mar 22 | 3 | -28 | 22 | 5 |
31 Dec 21 | 2 | -34 | 22 | 5 |
30 Sep 21 | 2 | -32 | 20 | 4 |
30 Jun 21 | 2 | -34 | 21 | 3 |
31 Mar 21 | 1 | -33 | 20 | 3 |
31 Dec 20 | 1 | -24 | 18 | 3 |
30 Sep 20 | 1 | -21 | 17 | 2 |
30 Jun 20 | 1 | -19 | 14 | 2 |
31 Mar 20 | 2 | -16 | 12 | 2 |
31 Dec 19 | 4 | -16 | 10 | 3 |
30 Sep 19 | 5 | -17 | 9 | 3 |
30 Jun 19 | 7 | -16 | 8 | 3 |
31 Mar 19 | 8 | -19 | 9 | 3 |
31 Dec 18 | 7 | -19 | 9 | 2 |
30 Sep 18 | 8 | -16 | 8 | 3 |
30 Jun 18 | 7 | -16 | 8 | 2 |
31 Mar 18 | 7 | -11 | 7 | 2 |
31 Dec 17 | 7 | -9 | 7 | 2 |
30 Sep 17 | 6 | -7 | 6 | 2 |
30 Jun 17 | 6 | -5 | 6 | 2 |
31 Mar 17 | 15 | 3 | 6 | 2 |
31 Dec 16 | 24 | 11 | 5 | 2 |
30 Sep 16 | 31 | 3 | 5 | 2 |
30 Jun 16 | 32 | 5 | 5 | 2 |
31 Mar 16 | 24 | -3 | 5 | 3 |
Quality Earnings: 3TP0 is currently unprofitable.
Growing Profit Margin: 3TP0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3TP0 is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare 3TP0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3TP0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Return on Equity
High ROE: 3TP0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.